iopromide has been researched along with Castleman Disease in 1 studies
iopromide: structure given in first source
iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.
Castleman Disease: Large benign, hyperplastic lymph nodes. The more common hyaline vascular subtype is characterized by small hyaline vascular follicles and interfollicular capillary proliferations. Plasma cells are often present and represent another subtype with the plasma cells containing IgM and IMMUNOGLOBULIN A.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YF | 1 |
| Zhang, WD | 1 |
| Sun, CZ | 1 |
| Ouyang, D | 1 |
| Chen, WK | 1 |
| Luo, RZ | 1 |
| Wu, MW | 1 |
1 other study available for iopromide and Castleman Disease
| Article | Year |
|---|---|
Clinical features and outcomes of head and neck castleman disease.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Castleman Disease; Chemotherapy, | 2012 |